Riskpilot← Back to searchSign inGet full accessV-BIOTEK HOLDING ApS
APSActiveCVR 30525299Græshave Alle 26Research and experimental development on natural sciences and engineering · NACE 7210Est. 2008— employees
Revenue 2025
DKK 57K
+7% vs 2024
EBITDA margin
-91.7%
-32% vs 2024
Equity ratio
20.8%
Financial strength
Net profit 2025
DKK 86K
+110% vs 2024
| Revenue | DKK 57K | +7% |
| EBITDA | DKK -52K | -32% |
| Net profit | DKK 86K | +110% |
| Total assets | DKK 7,7M | +71% |
| Equity | DKK 1,6M | +6% |
| Employees | — | — |
Legal name
V-BIOTEK HOLDING ApS
CVR number
30525299
Legal form
Anpartsselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
16. april 2008
Share capital
DKK 148.027
Employees
—
VAT registered
Yes
Audit selected
No
Last report
2025-06-30
Financial year
January – December
Signatory rights
Selskabet tegnes af den administrerende direktør alene.
Company purpose
Selskabets formål er at drive virksomhed inden for medicinalbranchen, branchen for naturlægemidler og hygiejneprodukter og enhver hermed beslægtet branche efter ledelsens skøn.
Address
Græshave Alle 26
Phone
+4523653600
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.586 | -575 | -245 | -549 | -253 | -89 | -204 | -16 | 389 | 239 | 43 | 67 | 53 | 57 |
| Staff expenses | -89 | -31 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBITDA | 4.497 | -5.009 | -272 | -549 | -253 | -89 | -204 | -16 | 389 | 239 | -70 | -71 | -39 | -52 |
| Depreciation & amort. | -0 | -25 | -25 | -775 | -775 | -774 | -750 | -750 | -750 | -750 | -750 | -750 | -750 | -750 |
| EBIT | 4.497 | -5.034 | -297 | -1.324 | -1.028 | -863 | -954 | -766 | -361 | -511 | -820 | -821 | -789 | -802 |
| Net financials | 1 | -4 | -123 | -21 | -51 | 89 | -370 | 7.377 | 264 | -8 | -1.264 | -77 | -76 | -1.031 |
| Profit before tax | 4.498 | -5.038 | -419 | -1.346 | -1.079 | -774 | -1.324 | 6.611 | -97 | -519 | -2.085 | -898 | -865 | 86 |
| Tax | -0 | -0 | -794 | -141 | -239 | -195 | -263 | -231 | -148 | -114 | -155 | -161 | -1 | -0 |
| Net profit | 4.498 | -5.038 | 374 | -1.205 | -840 | -579 | -1.061 | 6.842 | 52 | -405 | -1.930 | -737 | -864 | 86 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 20.534 | 16.026 | 15.667 | 9.653 | 8.982 | 7.703 | 9.409 | 7.249 | 7.181 | 7.686 | 5.971 | 5.190 | 4.478 | 7.651 |
| Equity | 16.365 | 11.327 | 11.701 | 6.555 | 5.715 | -394 | -1.454 | 5.387 | 5.439 | 5.034 | 3.105 | 2.368 | 1.504 | 1.590 |
| Long-term debt | -3.750 | -3.750 | -2.956 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 419 | 949 | 1.010 | 1.592 | 1.999 | 7.023 | 10.054 | 1.283 | 1.311 | 2.336 | 2.705 | 2.822 | 2.974 | 6.061 |
| Total debt | 419 | 949 | 1.010 | 1.592 | 1.999 | 7.023 | 10.054 | 1.283 | 1.311 | 2.336 | 2.705 | 2.822 | 2.974 | 6.061 |
EBITDA margin
-91.7%
This company
15.8%
Market median
-680% vs market
20122025
Equity ratio
20.8%
This company
38.2%
Market median
-46% vs market
20122025
Return on equity
5.4%
This company
18.4%
Market median
-71% vs market
20122025
Net profit margin
151.4%
This company
8.1%
Market median
+1769% vs market
20122025
Asset turnover
0.01×
This company
1.12×
Market median
-99% vs market
20122025
Debt / equity
3.81×
This company
0.62×
Market median
-515% vs market
20122025
- Annual report 2025Filed via CVR / Virk · Period 2024-07-01 – 2025-06-30
- Annual report 2024Filed via CVR / Virk · Period 2023-07-01 – 2024-06-30
- Annual report 2023Filed via CVR / Virk · Period 2022-07-01 – 2023-06-30
- Annual report 2022Filed via CVR / Virk · Period 2021-07-01 – 2022-06-30
- Annual report 2021Filed via CVR / Virk · Period 2020-07-01 – 2021-06-30
- Annual report 2020Filed via CVR / Virk · Period 2019-07-01 – 2020-06-30
- Annual report 2019Filed via CVR / Virk · Period 2018-07-01 – 2019-06-30
- Annual report 2018Filed via CVR / Virk · Period 2017-07-01 – 2018-06-30
- Annual report 2017Filed via CVR / Virk · Period 2016-07-01 – 2017-06-30
- Annual report 2016Filed via CVR / Virk · Period 2015-07-01 – 2016-06-30
- Annual report 2015Filed via CVR / Virk · Period 2014-07-01 – 2015-06-30
- Annual report 2014Filed via CVR / Virk · Period 2013-07-01 – 2014-06-30
- Annual report 2013Filed via CVR / Virk · Period 2012-07-01 – 2013-06-30
- Annual report 2012Filed via CVR / Virk · Period 2011-07-01 – 2012-06-30
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
JS Chief Executive Officer | Chief Executive Officer | 2022 | — | — |
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
VIRU ApS | Company | 66.7% | 66.7% | 2011 |
Redwood Foundation ApS | Company | 10.0% | 10.0% | 2024 |
ØYAN HOLDING ApS | Company | 10.0% | 10.0% | 2011 |
STEEN HANSEN HOLDING A/S | Company | 5.0% | 5.0% | 2011 |
SLANK ApS | Company | 5.0% | 0.0% | 2008 |
SVONI HOLDING ApS | Company | 5.0% | 5.0% | 2011 |
Schönherr Holding ApS | Company | 10.0% | 10.0% | 2011 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
SVONI HOLDING ApS
V-BIOTEK HOLDING ApS Board members of V-BIOTEK HOLDING ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Jens Steen Olsen | Chief Executive Officer | 0 companies |